Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | GHRHR | Q02643 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL121908 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL14060916 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189598 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL189599 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301510 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL301509 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL7109515 | 0.99 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL7109517 | 0.99 | TUBB4A (0.99) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL25052982 | 0.99 | NPC1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Docetaxel Anhydrous SCHEMBL22667521 | 0.99 | NPC1 (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 726 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149466-A1 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | FIGENE, LLC | 2023-05-18 | — | — | US | claimed |
| EP-4142753-A1 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| EP-3015137-B1 | ANTICANCER AGENT DECOMPOSITION METHOD AND ANTICANCER AGENT DECOMPOSITION DEVICE | TAMURA TECO CO LTD (JP) | 2022-10-26 | — | — | EP | claimed |
| US-20220280700-A1 | Temperature-Sensitive Hydrogel Composition for Preventing Tissue Adhesion, and Preparation Method Therefor | REGEN BIOCHARM CO LTD (KR) | 2022-09-08 | — | — | US | claimed |
| CN-114514043-A | Temperature-sensitive hydrogel composition for preventing tissue adhesion and preparation method thereof | 株式会社再生生物链 | 2022-05-17 | — | — | CN | claimed |
| WO-2021222943-A1 | IMMUNOTHERAPEUTIC METHODS AND COMPOSITIONS FOR TARGETING CANCER FIBROBLASTS | FIGENE, LLC (US) | 2021-11-04 | — | — | WO | claimed |
| WO-2021040493-A1 | TEMPERATURE-SENSITIVE HYDROGEL COMPOSITION FOR PREVENTING TISSUE ADHESION, AND PREPARATION METHOD THEREFOR | (주)리젠바이오참 | 2021-03-04 | — | — | WO | claimed |
| US-10034851-B2 | Metal-salen complex compound, local anesthetic and antineoplastic drug | IHI CORPORATION (JP) | 2018-07-31 | — | — | US | claimed |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | ISHIKAWA YOSHIHIRO (JP) | 2016-09-15 | — | — | US | claimed |
| WO-2016079331-A1 | GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2016-05-26 | — | — | WO | claimed |
| CN-102239138-A | Self-magnetic metal salen complex | IHI CORP (JP) | 2011-11-09 | — | — | CN | claimed |
| EP-2357166-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | IHI Corporation (JP) | 2011-08-17 | — | — | EP | claimed |
| US-20090169610-A1 | Liposome Preparation | SIEMENS AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | US | claimed |
| US-20090136577-A1 | Intestinal Absorptive Anti-Tumor Agent | KABUSHIKI KAISHA SANGI (JP) | 2009-05-28 | — | — | US | claimed |
| EP-1980243-A1 | LIPOSOME PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-15 | — | — | EP | claimed |
| EP-1872798-A1 | INTESTINAL ABSORPTIVE ANTI-TUMOR AGENT | KABUSHIKI KAISHA SANGI (JP) | 2008-01-02 | — | — | EP | claimed |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | D.WESTERN THERAPEUTICS INSTITUTE (JP) | 2006-06-15 | — | — | US | claimed |
| US-20050171036-A1 | Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | claimed |
| CN-1622814-A | Combined application of anti-tumor active indolopyrrolocarbazole derivative and other anti-tumor drugs | BANYU PHARMA CO LTD (JP) | 2005-06-01 | — | — | CN | claimed |
| EP-1498127-A1 | USE OF ANTITUMOR INDOLOPYRROLOCARBAZOLE DERIVATIVE AND OTHER ANTICANCER AGENT IN COMBINATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171036-A1 | Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination | IPO4, IPO5, IMPA1 | TUBB4A 918/4885TUBB 279/4885TUBA3C 107/4885 |
| US-10034851-B2 | Metal-salen complex compound, local anesthetic and antineoplastic drug | NCLN, KCNN2, NCSTN | TUBB4A 1683/4885TUBB 1247/4885TUBA3C 1495/4885 |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | TUBB4A 1683/4885TUBB 1247/4885TUBA3C 1495/4885 |
| US-20060128762-A1 | Medicinal composition and method for treating malignant tumor and utilization thereof | IL4I1, AADAT, BCAT2 | TUBB4A 41/4885TUBB 30/4885TUBA3C 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.